Discover proven strategies and insights refined over more than 5,000 launches around the world.
Join IQVIA Thought Leaders, Kirstie Scott and Stefan Lutzmayer, to explore how to translate the promise of ground-breaking oncology therapies into commercially successful launches. Learn about the evolving oncology landscape, and how to navigate a fluid and challenging commercial environment to achieve Oncology Launch Excellence.
Elyse Munoz, IQVIA’s US Director of Research and Insights, joins the podcast to discuss insights from the second paper of a three-part series, all about optimizing a US launch. Expect to learn about what impacts the optimization phase of a US launch: patient adherence, market access in the US context (and how it’s different from Europe), and direct-to-consumer advertising (prohibited in other major markets).
In episode 8, IQVIA EMEA Thought Leaderships’ lead on patient engagement, Meike Madelung, joins the podcast to talk about why patient engagement and support services (PES) are important for launch. Hear examples of how PES can benefit patients, healthcare systems, and pharma companies striving for launch success.
In this episode, Sarah Rickwood and Stefan Lutzmayer discuss key findings from the “From Orphan to Opportunity: Mastering Rare Disease Launch Excellence” white paper. Discover how to navigate the complex rare disease landscape, overcome post-pandemic hurdles, and apply the three pillars of launch excellence to achieve success in rare diseases.
Sarah Rickwood is joined by Elyse Muñoz, IQVIA’s US Director of Research & Insights, to discuss the first of a three-part launch excellence series on the current state of US launch and the new rules for launching excellently in the US, the most important market for global innovative medicines success.
In this episode, Sarah Rickwood and Kirstie Scott discuss key findings from the “Success Multiplied: Launch Excellence for Multi-Indication Assets” white paper. Learn about the specific challenges multi-indication assets face, such as sequencing and speed of indication roll-out, performance consistency across multiple indications and promotional investment strategies to capture pan-indication synergies.
IQVIA’s Head of Medical Affairs Strategy, Reinhard Berkels, joins Sarah Rickwood on the podcast to discuss the expanding role of Medical Affairs in launch. Hear how Medical Affairs is evolving and emerging as a more strategic function which can make or break a launch, and why this means companies should re-evaluate the way medical is positioned within their organization.
In Episode 3, Sarah Rickwood interviews Cristina Alzaga-Chaudhry, IQVIA’s EMEA Lead of Commercial Strategy & Transformation. Learn about agile launch planning, how launch performance management has evolved, and leading edge key performance indicators.
Sarah Rickwood and Kirstie Scott return in Episode 2 of the new Launch Excellence podcast series to discuss in more detail what companies should focus on in the challenging post-Pandemic environment. Expect to hear about the Three Pillars of post-Pandemic Launch Excellence and the elevated importance of healthcare system readiness to address the growing gap between the healthcare system preparation needs of many new launches and the ability of overstretched healthcare systems to meet those needs.
Sarah Rickwood and Kirstie Scott kick off the new Launch Excellence podcast series with a preview of their new white paper, Launch Excellence VIII. The authors discuss the evolving launch environment, post-Pandemic underperformance, resilient launches, and the latest insights on whether the "six-month window" holds in the challenging post-Pandemic environment.
How to capture the full potential of a pipeline in a product
The challenge of change: building Excellent launches in the post-pandemic environment
Discover proven strategies and insights refined over more than 5,000 launches around the world.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.